Grain Moxibustion Treatment on Insomnia: a Randomized Controlled Trial
Key facts
- Where
- Shanghai, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT04980703, who can take part
Where in China
- Shanghai Institute of Acupuncture, Moxibustion and MeridianShanghai, ChinaContact: Chunhui Bao, PhD,MDNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Shanghai Institute of Acupuncture, Moxibustion and Meridian
- Trial code
- NCT04980703
- Record updated
- 14 May 2025
- Original description
This trial intends to observe the clinical efficacy and safety of grain moxibustion at Baihui(GV20), Xinshu(BL15) and Pishu(BL20) in the treatment of insomnia.Read full original descriptionShow less
This trial intends to observe the clinical efficacy and safety of grain moxibustion at Baihui(GV20), Xinshu(BL15) and Pishu(BL20) in the treatment of insomnia.
Inclusion: Meet the diagnostic criteria of insomnia; TCM syndrome differentiation belongs to deficiency of both heart and spleen; Male or female participants aged 18-75; Participants whose PSQI score is 5-15; The course of disease is more than 3 months; Participants who voluntarily agree with the investigation and sign a written informed consent form for the clinical trial.
Exclusion: Taking sedative hypnotics (including barbiturates, benzodiazepines, tranquilizers, diphenylmethane, etc) and other insomnia related drugs within 2 weeks before the trial; Participants with dependence on sleeping drugs; Participants with serious cardiovascular diseases, liver, kidney and hematopoietic system diseases; Insomnia is caused by nervous system diseases (such as stroke, Parkinson's disease) or mental disorders (including depression or anxiety); Participants with diabetes and sensory dysfunction; Participants with skin diseases of acupoints; Participants suffering from malignant tumor, sequelae of severe cerebral apoplexy, organ failure and other major diseases that affect insomnia and therapeutic effect; Participants with mental retardation; Female participants who is pregnant or lactating.